Screener
D&A at other companies
Other financials
Where this comes from
Reported directly by Enliven Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:Depreciation.
The source filing: Enliven Therapeutics’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:17 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211982
| Line item | Three Months Ended March 31, 2026 | Three Months Ended March 31, 2025 |
|---|---|---|
| Cash flows from operating activities: | ||
| Net loss | $(23,627) | $(28,544) |
| Adjustments to reconcile net loss to net cash used in operating activities: | ||
| Depreciation | 14 | 74 |
| Stock-based compensation | 7,397 | 6,799 |
| Noncash lease expense | 93 | 85 |
| Amortization of premiums and discounts on marketable securities, net | 266 | (45) |
| Changes in operating assets and liabilities: |
Item 1. Condensed Consolidated Financial Statements (Unaudited)
FAQ
- What is Enliven Therapeutics's D&A?
- Enliven Therapeutics (ELVN) reported D&A of $14K in Q1 2026.
- How has Enliven Therapeutics's D&A changed year-over-year?
- Enliven Therapeutics's D&A decreased by 81.1% year-over-year, from $74K to $14K.
- What is the long-term trend for Enliven Therapeutics's D&A?
- Over 4 years (2021 to 2025), Enliven Therapeutics's D&A has grown at a 27.7% compound annual growth rate (CAGR), from $99K to $263K.
- What does D&A mean?
- Total non-cash depreciation of tangible assets and amortization of intangible assets — the largest add-back to net income in the operating cash flow reconciliation.
Ask your AI about Enliven Therapeutics's d&a.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude